Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BRAINSTORM CELL THERAPEUTICS INC.

Get SEC filing alerts via email and in your feed for BRAINSTORM CELL THERAPEUTICS INC.

BCLI

BRAINSTORM CELL THERAPEUTICS INC.

About BRAINSTORM CELL THERAPEUTICS INC.

BrainStorm Cell Therapeutics Inc. is a biotechnology company specializing in autologous cellular therapies for neurodegenerative diseases such as ALS, progressive multiple sclerosis, and Alzheimer’s. Its proprietary NurOwn® platform uses patients’ own bone marrow-derived mesenchymal stem cells induced to secrete neurotrophic factors, aiming to modulate neuroinflammation, promote neuronal survival, and improve neurological function. The company focuses on clinical development, manufacturing, and commercialization of these cell therapies primarily in the U.S. and Europe.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BRAINSTORM CELL THERAPEUTICS INC.

1
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Reports Q1 2026 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Inc. Reports $10.31 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Reports Q3 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Reports Q2 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Reports Q1 2025 Financial Results with Reduced Net Loss

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Reports $11.6 Million Net Loss for 2024, Focuses on NurOwn® ALS Trial

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Reports Financial Developments, Operating Losses, and Cash Decline in 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments